key: cord-0261103-azmrdmly
authors: Ma, J.; Joehanes, R.; Liu, C.; Keshawarz, A.; Huan, T.; Hwang, S.-J.; Bui, H.; Jejada, B.; Sooda, M.; Munson, P.; Demirkale, C.; Sharopova, N.; Feolo, M.; Courchesne, P.; Heard-Costa, N.; Pitsillides, A.; Ramachandran, V.; Levy, D.
title: Elucidating the genetic architecture of DNA methylation to identify promising molecular mechanisms of disease
date: 2022-04-16
journal: nan
DOI: 10.1101/2022.04.13.22273848
sha: 1156d253d9583f03917fc0cd33d9c7ffcabb06bf
doc_id: 261103
cord_uid: azmrdmly

DNA methylation commonly occurs at cytosine-phosphate-guanine sites (CpGs) that can serve as biomarkers for many diseases. We analyzed whole genome sequencing data to identify DNA methylation quantitative trait loci (mQTLs) in 4,126 Framingham Heart Study participants. Our mQTL mapping identified 94,362,817 cis-mQTLvariant-CpG pairs (for 210,156 unique autosomal CpGs) at P<1e-7 and 33,572,145 trans-mQTL variant-CpG pairs (for 213,606 unique autosomal CpGs) at P<1e-14. Using cis-mQTL variants for 1,258 CpGs associated with seven cardiovascular disease risk factors, we found 104 unique CpGs that colocalized with at least one cardiovascular disease trait. For example, cg11554650 (PPP1R18) colocalized with type 2 diabetes, driven by a single nucleotide polymorphism (rs2516396). We performed Mendelian randomization (MR) analysis and demonstrated 58 putatively causal relations of CVD risk factor-associated CpGs to one or more risk factors (e.g., cg05337441 [APOB] with LDL; MR P=1.2e-99, and 17 causal associations with coronary artery disease (e.g. cg08129017 [SREBF1] with coronary artery disease; MR P=5e-13). We also showed that three CpGs, e.g., cg14893161 (PM20D1), are putatively causally associated with COVID-19 severity. To assist in future analyses of the role of DNA methylation in disease pathogenesis, we have created a browsable and downloadable resource of mQTLs through the NCBI Molecular QTL Browser.

DNA methylation, the most frequently studied epigenetic modification, involves the transfer of a methyl group to the fifth carbon position of the cytosine DNA nucleotide to form 5-methylcytosine. 1 DNA methylation is influenced both by genetic and environmental factors and may mediate gene-environment interactions; therefore, it may be used to determine the risk of many complex diseases through its critical role in gene expression regulation. 2, 3 Associations between DNA methylation and a wide range of phenotypes have been identified by epigenome-wide association studies (EWAS). 4-6 DNA methylation therefore can serve both as biomarkers for disease and contribute to its pathogenesis.

Identification of genetic loci associated with the methylation of cytosine-phosphate-guanine sites (CpGs) -i.e., DNA methylation quantitative trait loci (mQTLs) -can facilitate the interpretation of the biological underpinnings regarding the DNA methylation and disease relations and causal inference regarding the roles of DNA methylation in disease. Genome-wide association studies (GWAS) have successfully identified many disease-associated genetic variants. 7 Molecular mechanisms linking these variants to disease, however, are not fully understood. Exploring colocalization of disease-associated genetic variants from GWAS with mQTL variants may further reveal molecular mechanisms underlying the associations between genetic variants and diseases. 8 We hypothesize that by studying the overlap of mQTL variants with known disease-associated genetic variants from GWAS, we can further explore the joint contributions of genetic and environmental influences to diseases. Furthermore, by colocalizing mQTLs with genetic variants associated with gene expression (expression quantitative trait loci, eQTLs), we can better interpret the biological functions of disease-associated CpGs. 8 Utilizing effect sizes derived from GWAS for mQTL variants with different diseases, we can conduct causal inference testing to explore the putative causal roles of CpGs on a wide range of diseases. [9] [10] [11] [12] [13] [14] In our earlier work, we performed GWAS of ~415,000 CpGs in whole blood derived DNA in Framingham Heart Study (FHS) participants with validation in the Atherosclerosis Risk in Communities . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 16, 2022. ;  https://doi.org/10.1101/2022.04.13.22273848 doi: medRxiv preprint (ARIC) study and the Grady Trauma Project (GTP). 15 Genotyping was performed using commercial arrays with imputation across the genome. The present study greatly expands on our prior work by incorporating whole genome sequencing (WGS) data in FHS participants obtained as part of the National Heart, Lung, and Blood Institute's (NHLBI) Trans-Omics for Precision Medicine (TOPMed) Program (https://www.nhlbiwgs.org/). Use of WGS greatly reduces imputation uncertainty and vastly increases coverage of variation across the human genome. In this study, we utilized state-of-the-art WGS in conjunction with DNA methylation measured by commercial arrays to quantify SNP-CpG associations in over 4,000 FHS participants. Our primary goal was to create a robust mQTL resource to better understand the genetic architecture of DNA methylation and facilitate the discovery of molecular mechanisms underlying a variety of diseases. We also provide examples of how mQTLs can be used in colocalization and Mendelian randomization (MR) analyses to infer the causal roles of DNA methylation in relation to disease phenotypes, with a focus on cardiovascular disease (CVD) risk factors and severity of coronavirus disease 2019 (COVID-19).

The study sample included consenting participants from the FHS Offspring, Third Generation, and Omni cohorts. In 1971, the FHS recruited the offspring of participants in the Original FHS cohort as well as the spouses of offspring to form the FHS Offspring cohort. 16 The children of the Offspring cohort participants were recruited to the Third Generation cohort beginning in 2002. 17 Omni cohorts were established in parallel with the Offspring and the Third Generation cohorts. In the current investigation, the study sample included 4,126 FHS participants with whole blood derived DNA methylation and WGS data; 2,129 participants in the Offspring cohort (exam 8, N=869; exam 9, N=1,260), 1,945 participants in the Third Generation cohort (exam 2), and 52 participants in the Omni cohort. The FHS protocols and procedures were approved by the , and all participants provided written informed consent.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 16, 2022. ; https://doi.org/10.1101/2022.04.13.22273848 doi: medRxiv preprint Study design. A flow chart of the study design is presented in Figure 1 . The FHS had two sets of DNA   methylation data, one set included 3,460 participants assayed with the Illumina BeadChip 450K (450K   array; 2,009 Offspring exam 8 participants and 1,451 Third Generation exam 2 participants) and the second set included 1,806 participants assayed with the Illumina EPIC array (EPIC array; 1,260 Offspring exam 9 participants, 494 Third Generation exam 2 participants, and 52 Omni cohort participants). To maximize the sample size, as our primary analysis we conducted a pooled analysis of the two data sets. Of note, 1,140 Offspring participants were included in both sets, i.e., these participants had 450K array-based methylation data from exam 8 and EPIC array-based methylation data from exam 9. In the pooled analysis, we selected the EPIC array-based data for these 1,140 participants to avoid any duplication. We also conducted array-specific analysis to explore if mQTLs were replicable and to examine mQTLs that are unique to the EPIC array. We then examined the top cis-and trans-mQTLs by conducting Gene Ontology (GO) pathway analysis and enrichment analysis. We tested cis-mQTLs for colocalization and causal association using two-sample MR analysis with CVD traits and COVID-19 severity.

DNA methylation profiling. Preparation of whole blood samples for DNA methylation profiling was conducted as detailed previously. 15 Briefly, DNA was obtained from whole blood buffy coat samples and prepared using bisulfite conversion before whole-genome amplification, fragmentation, array hybridization, and single-base pair extension. DNA methylation was then measured in 4,170 FHS participants using the Illumina Infinium Human Methylation-450 Beadchip (450K array) in three batches (Batch 1, N=499; Batch 2, N=2,149; and Batch 3, N=1,522). Of these, 3,460 participants also had WGS data. Additionally, the Illumina MethylationEPIC 850K BeadChip (EPIC array) was used in 1,806 FHS participants with WGS. All participants were with missing methylation levels of no more than 5% of CpGs (detection P<0.01) and none of them were outliers in a multi-dimensional scaling plot. The CpGs have been prefiltered so that all CpGs had < 5% missing values (detection P<0.01). We calculated DNA methylation beta values (range 0 to 1) as the ratio of mean methylated and sum of methylated and unmethylated probe signal intensities. We used the DASEN method 18, 19 to normalize the methylation beta . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 16, 2022 mQTL mapping. The mQTL mapping was conducted separately for DNA methylation data generated using the 450K array and the EPIC array. In the analysis for the 450K array data, we calculated residuals for methylation beta values obtained within each of the three methylation batches after adjusting for relevant technical covariates. Whereas, in the analysis for the EPIC array data, we derived residuals using all available samples, also adjusting for technical covariates. The residuals from separate datasets were then combined. We then used linear regression models to perform the association analyses between the SNPs and the CpGs, adjusting for sex, age, differential leukocyte counts (estimated using the Houseman method 21 ), along with the top 15 residual methylation principal components (PCs) and five genetic PCs.

We chose to adjust for 15 methylation PCs and five genetic PCs because this strategy resulted in the highest replication rate between the 450K array data and the EPIC array data. Because of relatedness among FHS study participants, linear mixed models were used in mQTL mapping to account for family structure. The primary pooled analysis examined 452,567 CpGs that are common to both arrays. The 450K array-specific analysis analyzed the same 452,567 CpGs and the EPIC array-specific analysis . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 16, 2022. ; https://doi.org/10.1101/2022.04.13.22273848 doi: medRxiv preprint examined 413,524 additional CpGs (i.e., CpGs not included in the pooled analysis). For cis-mQTLs (defined as within 1 million base pairs from the CpG site), we considered two-sided P<1e-7 to be statistically significant, whereas for trans-mQTLs (defined as located ≥ 1 million base pairs away from the CpG site or on a different chromosome), we considered two-sided P<1e-14 to be statistically significant.

The P value thresholds were selected for cis-mQTLs based on the Bonferroni correction for the number of CpGs tested (i.e., n=452,567) and for trans-mQTLs based on internal discovery-validation experiment that gave the highest trans replication rate. Because the number of SNPs analyzed in the two studies (~5 and ~9 million, respectively) was smaller than that tested in the present study (~20 million), we examined whether mQTLs identified in the two studies were also significant in our database.

Gene Ontology analysis. We tested the over-representation of GO terms based on genes annotated to the top 1,000 cis-mQTL variants (for 1,000 CpGs) with Entrez IDs identified by the pooled analysis. The default setting in the goana function from the R limma (Linear Models for Microarray and RNA-seq Data) package was used to conduct the GO analysis. 24 GO terms (Biological Process, Cellular Component, and Molecular Function) with false positive rate (FDR) <0.05 were reported. We repeated the same analysis for the top 1,000 trans-mQTL variants.

We analyzed all SNPs with association P<5e-8 included in the NHGRI-EBI GWAS Catalog (https://www.ebi.ac.uk/gwas/). 7 We identified 243,587 entries for 2,960 GWAS traits. In this analysis, we examined all mQTL variants with unique RSIDs in cis or trans at P<1e-7 or P<1e-14, . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 16, 2022. ;  respectively. Fisher's exact test was used to perform the enrichment analysis for each trait, and traits with FDR<0.05 were reported.

We conducted colocalization analysis using the R HyPrColoc package, a highly efficient deterministic Bayesian algorithm based on GWAS summary statistics. 25 We reported the posterior probability of full colocalization (PPFC). Default prior configuration parameters (prior.1=1e-4 and prior.c=0.02) and threshold of 0.7 for PPFC were used. We extracted cis-mQTL variants (P<1e-7) derived from the present pooled analysis for 1,258 CpGs associated with CVD risk factors in the EWAS catalog (P<1e-6) including BMI, waist circumference, fasting glucose, systolic blood pressure (systolic BP), diastolic blood pressure (diastolic BP), high-density lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol (LDL), and triglyceride. 6 We examined the colocalization of these CVD risk factor-associated CpGs with CVD-related traits including BMI, BP, lipid concentrations, type 2 diabetes, and coronary artery disease. Summary statistics for associations between cis-mQTL variants and GWAS SNPS for CVD-related traits were obtained from published GWAS databases. [26] [27] [28] [29] [30] [31] Mendelian randomization analysis. To showcase the potential use of the mQTL resource in causal inference analyses, we conducted MR analyses to infer causal associations of the CpGs with the abovementioned CVD-related traits and COVID-19 severity. In the MR analysis for CVD-related traits, we used the same cis-mQTL variants for the 1,258 CVD risk factors. COVID-19-associated CpGs were obtained from a recently published EWAS of COVID-19 severity. 32 We performed MR analyses using a two-sample MR approach. 33 We used independent cis-mQTL variants with pair-wise linkage disequilibrium (LD) r 2 <0.1 as instrumental variables (IVs). Using the TwoSampleMR R package, 34 we performed the primary analysis using the inverse variance weighted (IVW) method and sensitivity analysis using the MR-Egger method. We tested for potential horizontal pleiotropy by examining the MR-Egger intercept P value. The effect sizes and standard errors for IV-CpG associations were obtained from the pooled mQTL analysis. The effect sizes and standard errors for associations between IVs and CVD-. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 16, 2022. ; https://doi.org/10.1101/2022.04.13.22273848 doi: medRxiv preprint related traits were obtained from the published large GWAS described above. 26-28,30,31 We obtained effect sizes and standard errors from two GWAS for COVID-19 severity conducted by the COVID-19 Host Genetics Initiative 35 and the Genetics of Mortality in Critical Care (GenOMICC) study. 36 The COVID-19

Host Genetics Initiative included 8,779 cases (death or hospitalization requiring respiratory support due to COVID-19) and 1,001,875 population controls and the GenOMICC study included 7,491 cases (confirmed COVID-19 requiring continuous cardiorespiratory monitoring in intensive care units) and

48,400 population controls. Table 1 , our pooled analysis included 4,126 participants (2,320 with DNA methylation data from the 450K array and 1,806 with data from the EPIC array). In the FHS Offspring cohort, blood samples used for the 450K array measurements were collected ~6 years earlier than those for the EPIC array measurements, while blood samples for both arrays in the Third Generation cohort were obtained at the same visit. Therefore, the mean age for participants with EPIC array data was older than that for the 450K array. There were no substantial differences in sex, BMI, or other CVD risk factors. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 16, 2022. ; https://doi.org/10.1101/2022.04.13.22273848 doi: medRxiv preprint Enrichment analysis of mQTL GWAS signals. We examined 9,395,367 cis-mQTL variants and 5,820,451 trans-mQTL variants located in all autosomal chromosomes identified by the pooled analysis.

The enrichment analysis showed that, at FDR<0.05, the cis-mQTL variants were enriched with GWAS SNPs associated with 783 traits, representing 27.1% of the traits included in the GWAS Catalog. 7 For example, we found enrichment of SNPs associated with BMI (enrichment P=0 for BMI; Supplemental Table 6 ).

We tested 1,258 CVD risk factor-associated CpGs for colocalization with five CVD-related traits. We found that 104 unique CpGs colocalized with at least one CVD-related traits at PPFC threshold ≥ 0.7 (overall 155 colocalized pairs; Supplemental Table 7 ). In Table 2 , we present the top two CpGs that colocalized with each CVD-related trait. For example, cg11554650 (PPP1R18), a BMI-associated CpG on chromosome 6, colocalized with type 2 diabetes at SNP rs2516396 (PPFC=0.98), which explained 100% of the observed PPFC; cg05337441 (APOB), an LDL-associated CpG at chromosome 2, colocalized with coronary artery disease at rs668948 (PPFC=0.8), which explained 41% of the observed PPFC; and cg03676485 (LFNG), a HDL-associated CpG at chromosome 7, colocalized with systolic and diastolic BP at rs4632959 (PPFC=0.99), which explained ~100% of the observed PPFC.

Using the cis-mQTL variants for the 1,258 CVD risk factorassociated CpGs (P<1e-6) reported in the EWAS catalog, we conducted MR analysis to test for putatively causal relations of CVD risk factor-associated CpGs with the corresponding CVD risk factors (e.g., HDLassociated-CpGs with HDL and fasting glucose associated-CpGs with type 2 diabetes). After Bonferroni correction for the number of tests in analysis for each trait (e.g., 0.05/566 or 8.8e-5 in analysis for BMI), we identified 58 significant MR associations (Supplemental Table 8 ). The top three CpG-trait pairs were . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 16, 2022 . We also demonstrated that 17 CVD risk factor-CpGs were associated with coronary artery disease ( Table 3; corresponding P<3.9e-5), e.g., cg08129017 (SREBF1; reported as associated with BMI and triglyceride in the EWAS catalog; MR effect size: 1.81±0.25, P=5e-13) and cg02050917 (SKI; BMI-associated CpG; MR effect size: 2.65±0.39, P=1.4e-11).

A recent study conducted in 407 patients with COVID-19 showed that DNA methylation levels at 23 CpGs (located in 20 genes) were associated with COVID-19 severity. 32 We found that ten of the 23 COVID-19 severity-associated CpGs had at least one cis-mQTL variant in our database. We used independent cis-mQTL variants (linkage disequilibrium R 2 <0.1), which overlapped with the SNPs tested by the two COVID-19 severity GWAS, 35, 36 to conduct MR analyses. As shown in Table 4 , we observed that three CpGs, cg14893161 (PM20D1; P=6e-5 and 0.002 for the two COVID GWAS, respectively), cg17178900 (PM20D1; P=7e-4 and 0.008), and cg14859874 (UBAP2L; P=0.002 and 2e-4), were causally associated with COVID-19 severity after Bonferroni correction in analyses using both COVID GWAS databases.

To create a cutting-edge genome wide resource of cis-and trans-mQTLs, we analyzed whole genome sequences in conjunction with array-based DNA methylation data from 4,126 FHS participants. Our is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 16, 2022. ;  can be used to test causal relations of CpGs to multiple phenotypes such as CVD traits and COVID-19 severity. Our mQTL database is available in a browsable and downloadable format through the NCBI Molecular QTL Browser (https://preview.ncbi.nlm.nih.gov/gap/eqtl/studies/). Taken together, our study created a robust mQTL repository to better understand the epigenetic mechanisms underlying a wide range of diseases.

Consistent with our previous mQTL study 15 and others, 37,38 a majority of SNP-CpG pairs are cis. For example, the number of cis-mQTL-CpG pairs was 2.8 times of that of trans-mQTL-CpG pairs in our pooled analysis (1.5 times using P<1e -14) . To the best of our knowledge, our study is the largest mQTL mapping project using WGS, including ~20 million SNPs and INDELs and ~850 thousand CpGs. Our database expands the existing literature by adding ~40 million novel cis-and ~30 million trans-mQTL-CpG pairs based on WGS rather than imputed genotypes from array-based genotyping. In addition, our database included cis-and trans-mQTLs for 180,692 unique CpGs present on the EPIC array that are not on the 450K array. Compared to the older 450K array, the EPIC array increases CpG coverage of specific genomic regions such as enhancers and non-coding regions. 39 Therefore, our data therefore will facilitate future studies that examine the potential biological function and clinical impact of DNA methylation at these genomic regions.

To showcase the application of our mQTL database, we demonstrated the enrichment of mQTL variants for disease-associated SNPs from GWAS using the GWAS Catalog. 7 For example, analysis utilizing cis-mQTL variants showed enrichment for SNPs associated with CVD and multiple CVD risk factors including BMI, systolic BP, triglyceride, type 2 diabetes, and coronary artery disease. Our colocalization analysis using cis-mQTL variants for CpGs and GWAS summary statistics of these variants for CAD identified colocalization of an LDL-associated CpG, cg05337441 (APOB), with coronary artery disease.

A intergenic SNP rs668948, mapped to APOB and TDRD15, explained 41% of the observed colocalization. The product encoded by APOB is the main apolipoprotein of LDL that serves as the ligand . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 16, 2022. ;  for the LDL receptor. The atherogenic potential of apolipoprotein B-100 has been demonstrated by many studies including MR analysis. 28, [40] [41] [42] Our data are consistent with the notion that DNA methylation contributes to the atherogenicity of LDL and suggest that future studies are needed to examine the exact molecular underpinnings of these observations. Also, in line with these observations, our MR analysis showed that many CVD risk factor-associated CpGs are putatively causal for CVD and CVD risk factors (Supplemental Table 8 ). These findings provide epigenetic insights into associations reported in GWAS.

For example, we observed that cg12816198 (IRF5) was associated with systolic BP (MR P=6.3e-8) . SNP rs4728142, an intergenic variant mapped to genes IRF5 and KCP, has been reported to be associated with hypertension in previous GWAS. 43 This SNP (rs4728142) is a strong cis-mQTL variant for cg12816198 (IRF5; P=7e-215) and the leading instrumental variable in the MR analysis for systolic BP (single SNP MR analysis P=2.7e-9), suggesting a causal pathway whereby rs4728142 modifies DNA methylation levels at cg12816198 with downstream effects on systolic BP. Interestingly, both colocalization analysis and MR analysis showed a connection between cg27087650 (BCL3) and coronary artery disease through cis-mQTL variant rs62117206 (intronic to BCL3; P=3.6e-15; linkage disequilibrium R 2 =1 with rs4803750, another cis-mQTL variant of cg27087650; P=1.8e -14) . CpG cg27087650 is located in the gene body of BCL3, which encodes a protein functioning as a transcriptional co-activator through its association with NF-kappa B homodimers. Expression of BCL3 has been linked to CVD and cancer. [44] [45] [46] These examples provide proof of principle that integrating cis-mQTLs with CpGs and traits can reveal biological pathways by linking DNA methylation to a variety of diseases.

Our mQTL database can also be used to screen candidate DNA methylation sites for further consideration in experimental and interventional studies. This is exemplified by our MR analysis that revealed a putatively causal effect of COVID-19 associated CpGs on disease severity. Our COVID analysis focused on ten CpGs that were identified in a case-control study of COVD-19 severity. 32 Because of the retrospective design of the study, 32 it could not infer causal relations between DNA methylation at these CpGs and the severity of COVID-19. Our analysis highlighted three COVID-related CpGs annotated to . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 16, 2022. ; https://doi.org/10.1101/2022.04.13.22273848 doi: medRxiv preprint genes PM20D1 and UBAP2L that were putatively causal for COVID-19 severity; more research is needed to understand if and how these CpGs might influence outcome in patients with the COVID-19.

In parallel with our mQTL project, our research team is examining eQTLs and expression quantitative trait methylation sites (eQTM) using WGS, RNA sequencing, and DNA methylation resources obtained in FHS participants. The eQTL and eQTM resources are also available online via the NCBI Molecular QTL Browser (https://preview.ncbi.nlm.nih.gov/gap/eqtl/studies). These molecular resources enable users to explore how DNA methylation affects transcriptional activities and pathways leading to a wide range of disease phenotypes. These molecular resources can be used in concert to reduce bias due to reverse causality and unmeasured confounding, particularly environmental confounders. 47,48 Nonetheless, this study has several limitations that warrant discussion. Our analysis was conducted in a group of middleaged and older, primarily white adults; therefore, the findings in this study may not be generalizable to other populations. Nonetheless, we demonstrated that mQTLs identified in other studies, 22,23 including those identified in a cross-ancestry analysis, 23 were well replicated in our database. We captured whole blood-based DNA methylation profiles, which can serve as candidate biomarkers for diseases; however, they may not reflect tissue-specific DNA methylation levels, which may be relevant to specific diseases.

MR analysis was used to showcase the potential application of our mQTL database; however, MR analysis is based on assumptions that may not be testable. 49 Also, DNA methylation can be affected by both genetic and environmental factors. We did not attempt to test effect modification by environmental factors in this study. Future studies with larger sample sizes in diverse population are needed to replicate and expand our mQTL resource.

In conclusion, we have identified millions of cis-and trans-mQTL variant CpG pairs using state-of-theart WGS data in conjunction with high-throughput DNA methylation data. We demonstrated the utility of this vast mQTL resource by conducting GWAS signal enrichment analyses, colocalization, and MR . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 16, 2022. ;  analyses. Our mQTL repository is freely available via the NCBI Molecular QTL Browser for the scientific community to study the role of DNA methylation in health and disease.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 16, 2022 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 16, 2022 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 16, 2022. 

Epigenetic transgenerational actions of endocrine disruptors and male fertility

Inherited epigenetic variation--revisiting soft inheritance

The role of DNA methylation in mammalian epigenetics

Blood DNA methylation sites predict death risk in a longitudinal study of 12, 300 individuals

Blood Leukocyte DNA Methylation Predicts Risk of Future Myocardial Infarction and Coronary Heart Disease

The EWAS Catalog: A Database of Epigenome-wide Association Studies

Systematic Mendelian randomization framework elucidates hundreds of CpG sites which may mediate the influence of genetic variants on disease

Association of Body Mass Index with DNA Methylation and Gene Expression in Blood Cells and Relations to Cardiometabolic Disease: A Mendelian Randomization Approach

Genome-wide identification of DNA methylation QTLs in whole blood highlights pathways for cardiovascular disease

An investigation of coronary heart disease in families. The Framingham offspring study

The Third Generation Cohort of the National Heart, Lung, and Blood Institute's Framingham Heart Study: design, recruitment, and initial examination

A data-driven approach to preprocessing Illumina 450K methylation array data

The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic

Whole genome sequencing reveals host factors underlying critical Covid-19

Leveraging DNA-Methylation Quantitative-Trait Loci to Characterize the Relationship between Methylomic Variation, Gene Expression, and Complex Traits

Systematic evaluation of DNA methylation age estimation with common preprocessing methods and the Infinium MethylationEPIC BeadChip array

Association of Apolipoprotein B-Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis: Distinguishing Between Particle

Chr. Position